Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions

Autor: Puiggros, Anna, Collado, Rosa, Calasanz, M.J, Ortega, Margarita, Ruiz-Xivillé, Neus, Rivas-Delgado, Alfredo, Luño, Elisa, González, Teresa, Navarro, Blanca, García-Malo, MaDolores, Valiente, Alberto, Hernández, José Ángel, Ardanaz, María Teresa, Piñan, María Ángeles, Blanco, María Laura, Hernández-Sánchez, María, Batlle-López, Ana, Salgado Sánchez, Rocío Nieves, Salido, Marta, Ferrer, Ana, Abrisqueta, Pau, Gimeno, Eva, Abella Monreal, Eugenia, Ferrá, Christelle, Terol, María José, Ortuño, Francisco, Costa, Dolors, Moreno, Carol, Carbonell, Félix, Bosch José, Francesc Xavier, Delgado, Julio, Espinet i Solà, Blanca, Universitat Autònoma de Barcelona

Publikováno v: Oncotarget
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Digital.CSIC. Repositorio Institucional del CSIC

Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of complex karyotypes (CK) with or without hi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c33ee14ec31e9747ff312aaabe5987a
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=6351

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Adquisición de la inv(16)(p13q22) en un caso de crisis blástica de leucemia mieloide crónica en tratamiento con imatinib

Autor: Oñate, Guadalupe, Blanco, Maria Laura, Pratcorona, Marta

Publikováno v: In Medicina Clinica 17 May 2019 152(10):419-420

Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients.

Autor: Ramos-Campoy S; Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain., Puiggros A; Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain. apuiggros@imim.es., Beà S; Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain., Bougeon S; Oncogenomic Laboratory, Hematology Service, Lausanne University Hospital, Lausanne, Switzerland., Larráyoz MJ; Cytogenetics and Hematological Genetics Services, Department of Genetics, University of Navarra, Pamplona, Spain., Costa D; Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain., Parker H; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Rigolin GM; Hematology Section, St. Anna University Hospital, Ferrara, Italy., Ortega M; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain., Blanco ML; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Collado R; Department of Hematology, Consorcio Hospital General Universitario, Valencia, Spain., Salgado R; Cytogenetics Laboratory, Hematology Department, Fundación Jiménez Díaz, Madrid, Spain., Baumann T; Hematopathology Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain., Gimeno E; Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Applied Clinical Research in Hematological Malignances, Cancer Research Program, IMIMHospital del Mar, Barcelona, Spain., Moreno C; Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Bosch F; Department of Hematology, University Hospital Vall d'Hebron, Barcelona, Spain., Calvo X; Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain., Calasanz MJ; Cytogenetics and Hematological Genetics Services, Department of Genetics, University of Navarra, Pamplona, Spain., Cuneo A; Hematology Section, St. Anna University Hospital, Ferrara, Italy., Strefford JC; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK., Nguyen-Khac F; Hematology Department and Sorbonne Université, Hopital Pitie-Salpetriere, APHP, INSERM U1138, Paris, France., Oscier D; Department of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK., Haferlach C; MLL Munich Leukemia Laboratory, Munich, Germany., Schoumans J; Oncogenomic Laboratory, Hematology Service, Lausanne University Hospital, Lausanne, Switzerland., Espinet B; Molecular Cytogenetics Laboratory, Pathology Department, Hospital del Mar, Barcelona, Spain; Translational Research on Hematological Neoplasms Group, Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain. bespinet@parcdesalutmar.cat.

Publikováno v: Haematologica [Haematologica] 2022 Mar 01; Vol. 107 (3), pp. 593-603. Date of Electronic Publication: 2022 Mar 01.